Member Info for Notposting

Aldebaran, I wouldn’t be saying anything if he stopped posting completely fabricated nonsense. I had actually been pretty quiet today, but he chose to post unprovoked and tried to push yet another narrative, suggesting we had gone silent because we had supposedly bought back in. It seems to be a recurring habit of his.

It’s been answered, so you can keep asking. The answer will be the same. I can repost it if you like and it will be exactly the same way for emphasis. 😘

I’ll let the FCA do that 🫠

“The Group has not established clinical proof of concept for any of these product candidates.”

FCA-regulated individuals have personal obligations that extend beyond their firm role. They must act with honesty and integrity at all times. Publicly posting misleading statements, even outside work, can be a breach if it affects investor perceptions or the market. Only those explicitly authorised by the FCA can give investment advice, and providing advice on social media, forums, or elsewhere without authorisation is prohibited and may trigger enforcement action.

High standards of conduct are expected both professionally and in contexts where the individual is identifiable as FCA-regulated. Behaviour that undermines trust in the financial system or misleads investors could result in investigation or sanctions. If public statements are materially misleading or impact the market, Market Abuse Regulations (MAR) may also apply. FCA-regulated individuals are therefore personally responsible for avoiding misleading statements, unauthorised advice, and conduct that could harm investor confidence even outside their formal role.

I think someone has well and truly failed here.

LOL 😆 I’ve quoted key sections and emphasised points, which, last I checked, is part of the process. It isn’t difficult.

You, meanwhile, make moot points under a new alias that have no bearing on the overall argument.

I’ve also linked the prospectus for reference.

Nice try, though.

Concerned to see that someone who is FCA-regulated and on the board has posted multiple misleading statements and given advice on risk. That is worrying.

The phrases “Directors would use all endeavours to sell an interest in the development” and “reasonably certain” are hardly definitive statements, nor do they suggest any preferential route.

That said, it arguably shouldn’t matter. Allegedly, JustHereForFleecing knows 50% of the shareholders 😆 along with a number of so-called high-net-worth individuals who apparently have the time to watch the market all day, participate in WhatsApp groups, and definitely don’t need to sell stock to take part in placings, all while digesting and believing the nonsensical ramblings of a fleecer… allegedly.

Respectfully, the share price tells a different story. Funding remains the elephant in the room, as it is clearly insufficient and a significant amount required and that’s best case if there is no issues as trials continue. I’m not suggesting the company will go bust, but I did note that outcomes are unlikely to be favourable, and I’ve previously outlined all options.

The decline from the peak to the current level did not happen without reason. The market’s view is always broader than that of any single individual.

Well, it really depends on what I’m doing, who I happen to be at the moment, and whether I’m feeling long or short. So, hard to say, really.

But one thing is for sure they still have insufficient funding and will need ADDITIONAL WORKING CAPITAL OF £5.6 MILLION BY THE END OF JANUARY 2026 JUST TO CONTINUE its product development activities, which also means we are unlikely to see any progress on anything else either. Hope that helps.

Diggittt. I’m not. The company are. You insisted in posting it all, so I was happy to oblige.

Diggittt. There is no “fail safe” as you know, so let’s not mislead as I know you’re keen to never do that.

It is not guaranteed, as you seem to suggest. Being reasonably confident is not the same as certainty.

It is unlikely to be on favourable terms overall.

It is not a positive as you assume, as any sale would likely involve giving it away at a discount if you believe in the eventual value or potential. It is not something I would be touting, as it reads more like a last resort than a preferred course of action.

The fact remains that £5.6 million in funding is required by January. It is fairly clear that selling an interest is not the preferred option, nor is it sounding as it would likely to be favourable/ secure best value, and it would be unlikely to even be possible to conclude in a month. Inevitably, any attempt could cause delays, and that is assuming a sale can even be agreed.

Sorry, Diggittt. It seems I did. Let me finish it.

“If, ultimately, the Directors were unable to do so and had exhausted all other actions to fund the Company's product development through Phase 1 in respect of HG-CT-1, the Company would need to wind down its operations, realise its assets and may enter administration or liquidation in the period February to April 2026, if and to the extent there are creditors of the Company who cannot be paid. In such an event, the Company would no longer manage the affairs of the Company or the realisation of its assets. As a result of either winding down the business or entering into administration or liquidation, the Ordinary Shares would be cancelled from the Official List and Shareholders may receive little or no value for their Ordinary Shares.”

Finally, someone with sense.

Sounds more like Pingu 🫠

JustHereForFleecing lets recap what is important right now.

https://hemogenyx.com/wp-content/uploads/2025/11/Hemogenyx-Pharmaceuticals-plc-Prospectus-20251119.pdf

Read the official prospectus pointing out the following…

Don't forget they may need manufacturing runs too and in my opinion it’s unlikely you see the next treatment till late Q1/ early Q2 but it’s unknown at this stage as to where they are with that so granted could be earlier.

To address this anticipated funding shortfall, the Group will require ADDITIONAL WORKING CAPITAL OF £5.6 MILLION BY THE END OF JANUARY 2026 just to continue its product development activities with a primary focus on HG-CT-1 through to the end of 2026. A FURTHER £10 MILLION will be required from 2027 to 2028.

The Group will have INSUFFICIENT WORKING CAPITAL AFTER ADMISSION and further funds WILL BE REQUIRED in the first quarter of 2026 simply to continue operations and complete Phase I trials of HG-CT-1 in adult and paediatric patients.

The Company states clearly that working capital will be INSUFFICIENT FOR ITS PRESENT REQUIREMENTS for at least the next 12 months. Following Admission, Directors expect an AGGREGATE FUNDING SHORTFALL OF £15.6 MILLION.

Here comes JustHereForFleecing again, now with yet another alias. So let me get this straight: one of the many users you claim I am allegedly told you they are bitter, and now somehow I’m suddenly them, allegedly denying it, but with an alias instead, despite the fact that this person supposedly admitted it, but then never continued posting? Far‑fetched. Fascinating. 😆😆😆😆🫠

LOL 😆 he’s giving today.

It’s a bit rich coming from you, MrIndia, given your own needy track record on here, not to mention the WhatsApp echo chamber where you all reassure each other with the latest batch of misleading nonsense.

Aldebaran, what concerns me is that some of the more credulous individuals might take this at face value, and JustHereFleecing will then misrepresent it as you having ‘admitted’ that we are the same, framing it as if he’s uncovered some elaborate conspiracy. Please don’t.

I thought were placing some sort of weird order, Moorscloud.